2020 Fiscal Year Final Research Report
Molecular design of immunocytokines for control of regulatory T cell function
| Project/Area Number |
18K19567
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 54:Internal medicine of the bio-information integration and related fields
|
|---|
| Research Institution | Kobe Gakuin University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
井上 雅己 神戸学院大学, 薬学部, 助教 (80757097)
|
|---|
| Project Period (FY) |
2018-06-29 – 2021-03-31
|
| Keywords | TNFR2 / immunocytokine / 制御性T細胞 |
|---|
| Outline of Final Research Achievements |
In this project, we developed a new biologics which expands regulatory T-cells (Tregs) via TNFR2 signal activation. The biologics named immunocytokine (TNFR2-IC) is a recombinant fusion protein composed of anti-huTNFR2 single-chained Fv antibody (scFv) and huTNFR2-selective agonistic TNF-alpha mutant.TNFR2-IC bound to TNFR2 with high affinity and stimulated the proliferation of PBMC-derived effector Treg subset in vitro. These results indicate that the TNFR2-IC is promising as a Treg expander.
|
| Free Research Field |
分子細胞免疫学
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では、TNFR2のシグナリングとクラスタリングを誘導しうる新規バイオロジクスとしてTNFR2-ICを創製した。TNFR2-ICはin vitroにおいて、TNFR2アゴニストよりも効率よくヒトTregを増幅した。また、マウスへのTNFR2アゴニストの投与によってTregの増加が認められたことから、まだ検証はできていないが、TNFR2-ICの投与によっても同様に、Tregの効率的な増幅が期待できる。TNFR2-ICは、Tregの効率的な増幅作用を発揮しうることから、免疫疾患や移植医療における新たな創薬シーズになるものと期待される。
|
